Cariprazine Publications 2006-2020

Non-clinical

Chemistry
Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

Discovery of cariprazine (chemical aspects) (published in Hungarian) Open access
Domány Gy
Magyar Kémikusok Lapja 71: 261-262; 2016

The chemistry that lead to cariprazine (published in Hungarian with English abstract) Open access
Domány Gy, Greiner I
Magyar Kémiai Folyóirat 122: 112-116; 2016

Neurochemistry
Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile
J Pharmacol Exp Ther 333: 328-340; 2010

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
Psychopharmacology 218: 579-587; 2011

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites
Kiss B, Horti F, Bobok A
Synapse 65: 467-478; 2011

Synapse 67: 258-264; 2013

Long-Term Effects of Cariprazine Exposure on Dopamine Receptor Subtypes
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums 19: 268-277; 2014
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums, 22: 484-494; 2017

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity

Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N
Psychopharmacology 235: 1593–1607; 2018

Involvement of 5-HT1A and 5-HT2A receptors but not α2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo

Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P
Mol Pharmaco! 94: 1363-1370; 2018

The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens

Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY
J Pharm Exp Ther 371: 517-525; 2019

Pharmacology

RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and pro-cognitive effects in rodents

Neurochemistry International 59: 925-935; 2011

Cariprazine, a dopamine D3-receptor-preferred partial agonist, blocks phencyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C
Psychopharmacology 226: 91-100; 2013

Cariprazine (RGH-188), a D3-preferred dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats

Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z
Psychopharmacology 226: 285-293; 2013

Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression

Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I
Behav Pharmacol 25: 567-574; 2014

Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions

Gao Y, Peterson S, Masri B, Hougl!and MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS
Pharma Res Per 3: e00073, 1-10; 2014

Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices

El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N
Psychiatry Res 229: 370-373; 2015
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Open access
Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N
Eur Neuropsychopharmacol 26: 3-14; 2016

The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia
Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC
Eur Neuropsychopharmacol 26: 208-224; 2016

Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Open access
Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS
Int J Neuropsychopharmacol 20: 788-796; 2017

The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task. Open access
Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B
Psychopharmacology 235: 1403-1414; 2018

The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity. Open access
Delcourte S, Ashby CR, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N
CNS Neurosci. Ther. 24: 1129-1139; 2018

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Open access
Drug Des Develop Ther 13: 3229-3248; 2019

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices. Open access
Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z
Br J Pharmacol 1-13; 2020; doi: 10.1111/bph.14923

Pharmacokinetic
Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine
Pásztor Mészáros G, Ágai-Csongor É, Kapás M

Clinical
Schizophrenia
An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Open access
Schizophr Res 152: 450-457; 2014
Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. Open access
J Clin Psychiatry 76: e1574-e1582; 2015

Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. Open access

Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Open access
Int Clin Psychopharmacol 31: 61-68; 2016

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Open access
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovzky I, Fleischhacker WW, Nasrallah HA
Schizophr Res 176: 264-271; 2016

The effect of cariprazine on hostility associated with schizophrenia. Open access
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovzky I

Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial. Open access at Richter website
Lancet 389: 1103-1113; 2017

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. Open access
CNS Spectrums 23: 39-50; 2018

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study. Open access
Durgam S, Greenberg WM, Li D, Lu K, Laszlovzky I, Németh G, Migliore R, Volk S
Psychopharmacology 234: 199-209; 2017

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Open access
Earley W, Durgam S, Lu K, Laszlovzky I, Debelle M, Kane JM
Int Clin Psychopharmacol 32: 319-328; 2017

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis. Open access
BMC Psychiatry 17: 305; 2017
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Schizophr Res 204: 282-288; 2019

Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial
Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W
J Clin Psychiatry 80: 18m12495; 2019

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Eur Neuropsychopharmacol 29: 127-136; 2019

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Eur Psychiatry 58: 1-9; 2019

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia
Neuropsychopharmacol 44: 1589-1596; 2019

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W
Neuropsychiatr Dis Treat 15: 2537–2550; 2019

Mania
The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
Bipolar Disord 17: 63-75; 2015

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial

Cariprazine publications 2006 – 2020_v3
*J Affect Disord* **174**: 296-302; 2015

**Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder**
*J Clin Psychiatry* **76**: 284-292; 2015

**Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials**
Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S
*Eur Neuropsychopharmac* **25**: 1882-1891; 2015

**Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies**
Earley W, Durgam S, Lu K, Debelle M, Laszlovszyk I, Vieta E, Yatham LN
*J Affect Disord* **215**: 205-212; 2017

**The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study**
Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszyk I, Németh G
*J Affect Disord* **225**: 350-356; 2018

**Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder**
*J Affect Disord* **226**: 239-244; 2018

**Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials**
McIntyre RS, Masand PS, Earley W, Patel M
*J Affect Disord* **257**: 600-606; 2019

**Schizophrenia & Mania**

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis
*Int J Clin Pract* e13037; 2017

**Bipolar Depression**

An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression

**Cariprazine Treatment of Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study**
*Am J Psychiatry* **176**: 439–448; 2019
Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies Open access
McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM
CNS Spectrums; 2019, https://doi.org/10.1017/S1092852919001287

A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression Open access
Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN
J Affec Disord 263: 386-395; 2020

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial Open access
Yatham LN, Vieta E, Earley WR
Int Clin Psychopharmacol 35: 147–156; 2020

Major Depression add-on
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients Open access

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial Open access
Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G
Int Clin Psychopharmacol 33: 312-321; 2018

Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial
Earley W, Guo H, Németh G, Harsányi J, Thase M
Psychopharmacology Bulletin 48: 62-80; 2018

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder Open access
Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G
Int Clin Psychopharmacol 34: 76-83; 2019

Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study Open access
Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR
Bipolar Disord, 2019; DOI: 10.1111/bdi.12852

Human Pharmacokinetic
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO Open access
Psychopharmacology 233: 3503-3512; 2016

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Open access
*Drug Design Develop Ther* **10**: 327-338; 2016

*Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”*  
Periclou A, Riccobene T, Kapás M, Laszloszky I  
*Clinical Pharmacokinet* **58**: 1215-1216; 2019

*Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania*  

**Health Technology Assessment (HTA)**

*Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone*  
*J Comp Eff Res* **6**: 639-648; 2017

*Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia*  
*Health Policy Tech* **8**: 84-91; 2019

*Population-level QALY gain estimates with the use of cariprazine for patients with negative symptoms of schizophrenia in Hungary (Published in Hungarian with English abstract)*  
Bendes R, Németh B, Pitter JG, Kóczíán K, Götze Á, Kaló Z  
*LAM* **29**:467–475; 2019

**General**

*Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia. A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)*  
Laszloszky I, Németh G  
*Gyógyszerészet* **59**: 643-646; 2015

In nutshell about cariprazine (Published in Hungarian)  
Laszloszky I, Barabássy Á  
*Psychiatric and Neurology Times – Hungarian edition, (5) 26-28, 2018*

*Cariprazine, a new type – dopamine D₃ receptor preferring – partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms. (Published in Hungarian with English abstract)*  
Laszloszky I, Kiss B, Barabássy Á, Kapás M, Németh G  
*Neuropsychopharmacol Hung* **21**: 103-118; 2019